A PHASE 1, NON-RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-07321332 BOOSTED WITH RITONAVIR IN ADULT PARTICIPANTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
Latest Information Update: 07 Sep 2023
Price :
$35 *
At a glance
- Drugs Nirmatrelvir (Primary) ; Nirmatrelvir+ritonavir (Primary) ; Ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 18 Jan 2022 Status changed from recruiting to completed.
- 26 Oct 2021 Planned End Date changed from 30 Nov 2021 to 4 Dec 2021.
- 26 Oct 2021 Planned primary completion date changed from 30 Nov 2021 to 4 Dec 2021.